RICHARD MILLER: Open Payments
NPI 1114122595 · EAST GREENWICH, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$261,416 in 323 payments from 9 companies in 2025. Trend: 2023 $110,331 · 2024 $224,266 · 2025 $261,416
Speaker / faculty: $189,958Consulting: $45,507Travel & lodging: $18,205Food & beverage: $7,635Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 108 | $144,851 |
| Janssen Pharmaceuticals, Inc | 76 | $52,553 |
| Alkermes, Inc. | 57 | $32,997 |
| Otsuka America Pharmaceutical, Inc. | 30 | $18,602 |
| E.R. Squibb & Sons, L.L.C. | 44 | $12,215 |
| Indivior Inc. | 3 | $81 |
| Neurocrine BioSciences, Inc. | 3 | $71 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: UZEDY, AUSTEDO XR, INVEGA SUSTENNA, REXULTI, ARISTADA, LYBALVI, COBENFY, VIVITROL.
Industry payments across RI — which companies pay providers there.
